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Abstract: The care of older patients with cancer is becoming increasingly complex. 
Common challenges for this population include management of comorbidities, safe transi-
tions of care, and appropriate medication use. In particular, polypharmacy—generally 
defined as the regular use of five or more medications—and inappropriate medication use 
can lead to adverse effects and poor outcomes in older adults with cancer, including falls, 
hospital readmissions, cognitive impairment, poor adherence to essential medications, che-
motherapy toxicity, and increased mortality. Managing polypharmacy across different cancer 
care settings is often challenging. Providers face barriers to safe and successful medication 
management that may include lack of time, absence of reimbursement, underappreciation of 
the scale of polypharmacy-related harm, lack of ownership of deprescribing efforts, and poor 
communication across care settings. Existing literature on managing inappropriate medica-
tion use and polypharmacy in older adults with cancer has often focused on ideal state 
settings in which resources are plentiful and time is purposefully allocated for medication 
interventions. This paper presents a narrative, rather than a systematic review, of studies 
published in the past decade that provided detailed information on medication management 
and polypharmacy across cancer care settings. This review aims to also summarize different 
healthcare provider roles in taking action against inappropriate medication use and poly-
pharmacy in older adults with cancer. 
Keywords: geriatric oncology, polypharmacy, potentially inappropriate medication, 
medication management, deprescribing, cancer care setting, interprofessional team
Introduction
The care of older patients with cancer is becoming increasingly complex. This 
complexity may comprise management of comorbidities, safe transitions of care, 
and appropriate medication use. In particular, polypharmacy—generally defined as 
the regular use of five or more medications—and inappropriate medication use can 
lead to adverse effects and poor outcomes in older adults with cancer, including 
falls, hospital readmissions, cognitive impairment, poor adherence to essential 
medications, chemotherapy toxicity, and increased mortality.1
Healthcare experts have noted that addressing such medication use represents an 
important opportunity to improve medical care for older adults.2 However, mana-
ging polypharmacy across different cancer care settings is often challenging. 
Barriers for providers to safely and successfully manage medications include lack 
of time, absence of reimbursement, underappreciation of the scale of polyphar-
macy-related harm, lack of ownership of deprescribing efforts, and poor commu-
nication across care settings.3,4 Many of these challenges can be abated by the 
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introduction of clinical pharmacy services, with several 
studies showing positive benefits when pharmacists are 
added to the care team for older adults with cancer.5,6
Existing literature on managing inappropriate medica-
tion use and polypharmacy in older adults with cancer 
has often focused on ideal state settings in which 
resources are plentiful and time is purposefully allocated 
for medication interventions. In real life, this ideal state is 
often not feasible in different cancer care settings. For 
instance, while larger academic medical centers may 
have multiple dedicated pharmacists to conduct medica-
tion reviews, small hospitals may not. Thus, our paper 
presents a narrative, rather than a systematic review, of 
studies published in the past decade that provided 
detailed information on medication management and 
polypharmacy across cancer care settings. These studies 
included cohorts of patients diagnosed with solid tumor 
malignancies, hematologic malignancies and surgical 
oncology patients.
With our narrative review, we aim to summarize 
different healthcare provider roles in taking action 
against inappropriate medication use and polypharmacy 
in older adults with cancer (Box 1 describes how to use 
this review). It is the first review of its kind to summar-
ize potential clinician roles in evaluating polypharmacy 
in various cancer care settings. Each section describes 
nuances and differences in priorities within each care 
setting aimed at combating polypharmacy in older adults 
with cancer as detailed in Table 1. Along with noting 
differences in care setting priorities, this paper empha-
sizes the importance of examining individual patient 
context when making medication-related decisions. For 
older adults with cancer, geriatric syndromes (eg, falls, 
frailty, cognitive impairment, mobility issues) and the 
issue of chronologic age versus functional age can be 
directly aligned with polypharmacy assessments and 
deprescribing decisions. Todd et al7 recently explored 
patient context as it relates to deprescribing recommen-
dations and developed a conceptual framework called 
“the deprescribing rainbow” that considers clinical, psy-
chological, social, financial, and physical determinants 
for assisting with deprescribing decisions. The global 
themes of the deprescribing rainbow framework high-
light the heterogeneity of the older adult population and 
acknowledge the evolving care needs of the individual 
patient; these themes are consistent with the established 
role of person-centered care in managing medications in 
older adults with cancer.7
Finally, this review attempts to identify gaps in 
knowledge and lay out areas of interest for future 
research efforts. It should be noted that even within 
seemingly identical care settings, there may be unique 
challenges that prevent optimal services. One example is 
use of screening tools to identify polypharmacy and 
potential inappropriate medication (PIM) use. While 
screening tools are not required for identifying polyphar-
macy and PIMs, they can certainly streamline the pro-
cess. For some clinicians, awareness and implementation 
of a screening tool may not be a part of their routine 
workflow while caring for older adults with cancer. It is 
also important to note that not all screening tools are 
specific to older adults with cancer, and some tools are 
more user friendly than others. Existing data support the 
application of three medication screening tools for older 
adults with cancer: Beers Criteria, Medication 
Appropriateness Index (MAI), and the Screening Tool 
of Older Persons’ Prescriptions (STOPP). Beers Criteria 
and STOPP are both explicit screening tools that help 
clinicians quickly screen for inappropriate therapies 
based on potential medication-induced harm or disease- 
medication discrepancies. The MAI is an implicit scor-
ing-based tool that helps determine appropriateness based 
on a defined set of criteria (eg, indication, efficacy, 
dosage, directions, cost, drug–drug interactions, drug– 
disease interactions, and medication duplication); each 
medication screened with the MAI is subsequently 
deemed to be inappropriate, marginally appropriate, or 
appropriate. An extensive review of screening tools for 
PIMs and polypharmacy in the context of geriatric oncol-
ogy is beyond the scope of this review but has been 
described elsewhere.3,8
Box 1 How to Use This Review
● Review the entirety of this paper or jump to the applicable section 
according to individual discipline or work setting (eg, a nurse 
practicing in outpatient clinics may obtain the most benefit from the 
text and corresponding tables in the “ambulatory setting” section).
● Each row within the table outlines the various roles of clinicians in 
different care settings and indicates where overlap of practice and 
concepts exist.
● Consider the bottom line recommendation box a “call to action” 
on what the authors consider the most evidence-based area or idea 
worth exploring in future research on polypharmacy in older adults 
with cancer.
● Clinicians are encouraged to make simple changes and adopt what 
makes sense for their practice site. Applying all recommendations in 
a specific care setting may not be feasible initially.
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● Flag prescribing inertia at time 
of admission to hospital, espe-
cially for patients admitted 
through the emergency 
department.
● Involve patients and caregivers 
in the deprescribing process 
(eg, keep patients up-to-date on 
any medication changes).
● Promote awareness of depre-
scribing services on the inpati-
ent units (eg, market services to 
providers and patients alike).
● Champion the formation of an 
Oncology-Acute Care for 
Elders unit with a focus on 
polypharmacy assessment.
● Recognize common instances of 
prescribing inertia (eg, if reason 
for admission is due to compli-
cations from a fall, medications 
should always be considered 
a potential contributing factor).
● Promote awareness of depre-
scribing services on the inpati-
ent units (eg, recommend 
available pharmacists services to 
patients and caregivers).
● Work with an interprofessional 
team to flag barriers to depre-
scribing (eg, inability to coordi-
nate with outside specialist 
physicians).
● Promote proactive assess-
ments of potentially inap-
propriate medication therapies 
(eg, bring concerns to phar-
macists and providers as soon 
as possible).
● Collaborate with pharmacy 
staff in potential Oncology- 
Acute Care for Elders 
rounding.
● Utilize tools to complete 
screening for delirium and falls.
● Continuation of inappropriate 
therapies is common in the 
hospital setting; breaking pre-
scribing inertia can successfully 
occur during hospital 
admissions.
● Interprofessional team resources 
are necessary to manage falls and 
delirium related to inappropriate 
medication therapies.
● Deprescribing is feasible during 
a hospital stay; therefore, clini-
cians should promote awareness 
of the available service to col-






● Perform comprehensive medica-
tion reconciliation (drug name, 
strength, route, frequency, 
duration, indication) using the 
patient provided list, electronic 
medical record, records from 
outside pharmacy and claims 
data.
● Assess medication adherence.
● Perform an independent review 
of the reconciled medication list 
using the patient provided list, 
electronic medical record.
● Collaborate with an interprofes-
sional team (eg, licensed inde-
pendent practitioners, 
pharmacists, nurses, social 
work) to optimize medication 
use.
● Flag patients that may benefit 
from a comprehensive medica-
tion review.
● Aim to deter preventable hospi-
talizations and emergency 
department visits.
● Develop a process for conduct-
ing periodic comprehensive 
medication reviews for patients 
in need.
● Evaluate cancer-related medica-





● Perform comprehensive medica-
tion review in order to optimize 
medication use (eg, assessing 
indication, limiting side effects, 
limiting drug–drug interactions, 
assessing cost, limiting pill 
burden).
● Assess the need to discontinue 
certain high-risk medications 
before surgery (eg, fall-inducing 
medications, delirium-inducing 
medications, medications that 
increase bleeding risk).
● Ensure that medications have 
been reviewed prior to the sur-
gery in order to reduce the risk 
of post-surgical adverse events 
(eg, falls, delirium).
● Promote proactive medication 
reviews for patients.
● Work collaboratively with 
pharmacy staff to optimize 
medication use (eg, communi-
cating pill burden, side effects, 
patient specific factors).
● Recognize and screen for med-
ications associated with delir-
ium and falls.
● Communicate medication 
changes, discontinuations or 
new prescriptions with 
patients upon discharge.
● Develop a process for perform-
ing comprehensive medication 
reviews as a routine part of the 
pre-surgical assessment.
● Multidisciplinary resources are 
necessary to manage falls and 





● Ensure cancer therapy is appro-
priate based on patient’s disease, 
functional age, comorbidities, 
and goals of care.
● Provide education to patients 
regarding their regimen and 
particular side effects that may 
be more common based on 
their functional age.
● Educate infusion center staff on 
ways to identify PIMs in older 
adults (eg, Beer’s criteria, 
STOPP/START criteria, review 
high risk medications).
● Assess the appropriateness of 
cancer therapy based on 
patient’s disease, functional age, 
comorbidities, and goals of care.
● Evaluate effectiveness of therapy 
and supportive care regimens, 
and deprescribe agents in which 
the risks outweigh the benefit.
● Assess patient before cancer 
therapy (infusions) to ensure 
treatment parameters are met. 
Ensure appropriate line access 
for treatment.
● Assess patient during and after 
infusion, monitoring for side 
effects or reactions.
● Communicate medication 
changes, discontinuations, or 
new prescriptions with 
patients.
● Work with an interdisciplinary 
team to develop a process to 
review medications and cancer 
therapy to ensure treatment is 
appropriate for each patient 
based on their individual factors.
● Communicate medication 
changes, discontinuations or 
new prescriptions with patients, 
while providing thorough 
education.
(Continued)
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Table 1 (Continued). 
Practice 
Setting





● Perform comprehensive medica-
tion review in order to optimize 
medication use and minimize risk 
of adverse drug events (eg, 
assessing indication, limiting side 
effects, limiting drug–drug inter-
actions, assessing cost, limiting pill 
burden)
● Evaluate cancer-related medica-
tions and medications for other 
comorbid conditions.
● Ensure chemotherapy orders 
are verified appropriately based 
on appropriate dosing and per-
tinent laboratory values.
● Develop a process to double 
check the appropriateness of 
cancer therapy based on 
patient’s disease, functional age, 
comorbidities, and goals of care.
● Promote proactive medication 
reviews for patients.
● Work collaboratively with 
pharmacy staff to optimize 
medication use (eg, communi-
cating pill burden, side effects, 
patient specific factors).
● Communicate medication 
changes, discontinuations or 
new prescriptions with 
patients upon discharge.
● Collaborate with an interprofes-
sional team to ensure cancer 






● Align medication decisions with 
knowledge of patient life expec-
tancy and individual medication 
goals (eg, avoidance of sedating 
medications early in the day to 
promote alertness).
● Consider patient’s ability to 
swallow or chew and the 
impact on medication dosage 
form decisions (eg, loss of oral 
access necessitating sublingual 
administration).
● Approach deprescribing deci-
sions systemically in an effort 
to minimize deprescribing fail-
ures and unwanted hospital 
readmissions; support decisions 
using standardized deprescribing 
frameworks.
● Deprescribe medications based 
on remaining life expectancy of 
the patient, time until benefit of 
the medication, individual 
patient goals of care, and the 
intended target of the 
treatment.
● Establish roles and responsibil-
ities of deprescribing efforts 
amongst provider colleagues (eg, 
assigning ownership to primary 
care provider versus 
oncologist).
● Empower nursing colleagues to 
take the lead in flagging medica-
tion related problems; empower 
through communication and 
protocol development.
● Monitor for signs of new med-
ication adverse effects or 
withdrawal symptoms after 
deprescribing.
● Educate patients and caregivers 
on potential medication 
adjustments, monitoring, and 
the appropriate use of “emer-
gent” therapies.
● Consider patient’s ability to 
swallow or chew and the 
impact on medication dosage 
form decisions (eg, loss of oral 
access necessitating sublingual 
administration).
● Collaborate with pharmacists 
to develop rationale for medi-
cation management to present 
to the team.
● Align medication therapies with 
goals of care, particularly utiliz-
ing therapies that improve or 
maintain quality of life.
● Utilize strategies for deprescrib-
ing that prevent medication 
withdrawal and unwanted emer-
gency department visits and 
hospital readmissions.
● Explore the role of nurses in 
medication management in the 






● Perform comprehensive medica-
tion review in order to optimize 
medication use and minimize the 
use of
● PIMs.
● Educate patient regarding che-
motherapy and/or supportive 
care regimens, highlighting side 
effects or special considerations 
(eg, drug storage, how medica-
tion is best taken).
● Discuss affordability and ensure 
delivery of medications.
● Assess medication adherence by 
talking with the patient and 
reviewing refill history.
● Assess the appropriateness of 
cancer therapy based on 
patient’s disease, functional age, 
comorbidities, and goals of care.
● Communicate with specialty 
pharmacy staff when changes 
occur in the patient’s cancer 
regimen (eg, dosage changes, 
start of new medications, dis-
continuation of medications).
● Collaborate and communicate 
with specialty pharmacy staff 
regarding medication changes, 
discontinuations or new 
prescriptions.
● Promote medication 
adherence.
● Collaborate with an interprofes-
sional team to
● ensure cancer therapy and sup-
portive care regimens are 
appropriate.
● Provide thorough education and 
assess medication adherence 
and ensure affordability and 
access to medications.
http://doi.org/10.2147/DHPS.S255893                                                                                                                                                                                                                                 
DovePress                                                                                                                                            
Drug, Healthcare and Patient Safety 2021:13 104
Whitman et al                                                                                                                                                        Dovepress
Academic Medical Center Inpatient 
Setting
Many patients who are hospitalized—especially patients 
with cancer—are taking multiple medications, including 
medications that are no longer needed or that potentially 
contribute to hospital admission or readmission.9 The 
inpatient academic medical center (AMC) setting pre-
sents challenges and barriers to polypharmacy assess-
ment and deprescribing.10–13 For example, inappropriate 
prescribing inertia is common in the inpatient setting, 
and polypharmacy assessment and deprescribing are 
commonly limited to reactive processes, such as in 
response to an adverse drug reaction, rather than proac-
tive, especially in teaching hospitals.14
But AMCs may also offer an ideal environment for 
deprescribing due to the collaborative environment, time 
for detailed medication histories, and engagement of 
families and caregivers in the deprescribing process during 
the hospital stay.15,16 For older adults with cancer, the 
AMC can be an appropriate environment to study poly-
pharmacy due to the multidisciplinary cancer care, focus 
on education/scholarship, and longer lengths of stay. 
Furthermore, research in the general geriatric population 
has shown that inpatient deprescribing initiatives are fea-
sible and safe and that they are successfully continued 
after hospital discharge.10
There is currently a literature gap on the impact of 
polypharmacy and deprescribing interventions specifically 
in the AMC. The only study on the impact of 
a multidisciplinary team to reduce polypharmacy in older 
adults with cancer is an observational study by Flood 
et al.17 The study outlined a model for combating poly-
pharmacy within a novel Oncology-Acute Care for Elders 
(OACE) unit that served as an interdisciplinary consulta-
tion service aimed at recognizing and managing geriatric 
syndromes. The OACE team consisted of bedside nursing 
and a geriatric clinical nurse specialist, hospice nurse, 
geriatrician, clinical pharmacist, registered dietician, social 
worker, and case manager. A key component of the OACE 
was formal ongoing education, provided mostly by the 
clinical pharmacist, on geriatric syndromes, polypharmacy, 
and the use of high-risk medications. Researchers used the 
Beers Criteria to assess for PIMs and noted non-Beers 
medications as high-risk based on perceived likelihood of 
causing harm (eg, delirium, falls). The most commonly 
prescribed PIM was diphenhydramine. Out of 47 patients 
in the study, 53% had their medication regimen altered and 
about a third had a PIM discontinued. This model could be 
modified even further to create an inpatient polypharmacy 
consultation service or be formally integrated with inpati-
ent rounding services for oncology units.
Other studies on the impact of polypharmacy in hospi-
talized patients with cancer include a small pilot study by 
Mort et al18 that evaluates a pharmacist-led deprescribing 
intervention in hematopoietic stem cell transplant patients. 
The pilot study was designed as a result of internal quality 
data showing that the inpatient stem cell transplant popu-
lation experienced a high incidence of falls, mostly attrib-
uted to medication-related adverse effects (eg, delirium, 
vasovagal falls).19 The average age of patients in this 
study was 65 years old and the median length of admission 
was 21 days. The major endpoints of the study included 
incidence of PIMs, percentage of PIMs successfully depre-
scribed, incidence of drug–drug interactions (DDIs), com-
parison of home and discharge polypharmacy, and fall 
events. Patients were screened for polypharmacy (≥5 med-
ications) and PIMs (using sequential application of Beers, 
STOPP, and the MAI) during an outpatient pre-transplant 
visit. After admission, the pharmacist completed a five- 
step deprescribing process. A total of 33 PIMs were iden-
tified for nine patients. Of these, a total of 22 of the 33 
PIMs (67%) were successfully deprescribed. Most com-
mon drug classes deprescribed were analgesics and vita-
mins/minerals. Sixteen drug interactions were noted, most 
commonly between ciprofloxacin and vitamins/minerals. 
After the deprescribing intervention for the nine patients, 
polypharmacy was reduced by 11% from admission to 
discharge. No patients in the study experienced a fall 
event. This was the first study to apply a deprescribing 
intervention in the hospital setting for patients undergoing 
stem cell transplant.
Several studies have described the impact of specific 
medications or medication classes on delirium in older 
adults with cancer in the AMC. One study evaluating 
geriatric syndromes on an OACE found that several 
patients were taking high-risk medications, including 
diphenhydramine to prevent infusion reactions prior to 
anticancer treatments or as part of transfusion protocols. 
Diphenhydramine in hospitalized older adults has been 
associated with an increase in urinary retention and delir-
ium. The authors noted that the majority of the OACE 
patients who received diphenhydramine prior to a blood 
transfusion did not have a history of any infusion 
reaction.20 Another study by Gaudreau et al21 found that 
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exposure to opioids, benzodiazepines, and corticosteroids 
was associated with an increased risk of delirium in hos-
pitalized older adults with cancer. This study did not find 
an association with anticholinergic therapies and delirium 
risk.
A review by Marvin and Jubraj22 explored polyphar-
macy in the hospital environment in the general older adult 
population and found that ordering medications was the 
most common intervention that occurs in the acute care 
setting. The authors identified several points of care during 
a hospital stay in which a polypharmacy assessment may 
occur: pre-admission to the hospital, before and after sur-
gical procedures, worsening of long-term conditions, diag-
nosis and treatment of a new disease alongside other 
preventative therapies, and preparing for hospital dis-
charge. Each of these points of care could be explored 
further in older adults with cancer.
Several other studies touch upon the issue of polyphar-
macy that have the potential to be new areas of research 
for older adults with cancer, specifically in academic med-
ical centers, including the development of health system 
standard work/guidance tools for inpatient polypharmacy 
management; the need for educating new clinicians and 
students about polypharmacy and its harms; the role of 
empowering patients to become engaged with inpatient 
medication reviews; and creating awareness that depre-
scribing is an option for patients in the hospital.23–28 
More studies are also needed to define the potential roles 
of non-pharmacist clinicians (eg, physicians, advanced 
practice providers, nurses) on tackling polypharmacy. Of 
note, collaborative deprescribing interventions that include 
patients, physicians, and pharmacists may be more effec-
tive than less-inclusive interventions.29
Academic Medical Center 
Ambulatory Care Setting
Several barriers to polypharmacy assessment may exist in 
the AMC outpatient setting compared to the inpatient 
setting, including clinicians having less available time 
to spend with the patient and fewer personnel being 
available to complete the medication review. But the 
ambulatory setting within an AMC provides multiple 
opportunities to assess polypharmacy and other medica-
tion-related concerns in older adults with cancer. These 
opportunities include medication review by a nurse or 
doctor during a routine oncology visit; a targeted review 
by a pharmacist integrated into the oncology clinic; and 
a polypharmacy assessment in a multidisciplinary clinic 
that includes a pharmacist. Exactly when and how to 
incorporate the polypharmacy-related medication review, 
however, can vary.
Studies have demonstrated different approaches to 
accomplishing polypharmacy assessment in older adults 
with cancer in the ambulatory setting. In one pilot study 
by Ramsdale et al,30 older adults with cancer were admi-
nistered a geriatric assessment (the provider performing 
the polypharmacy assessment was not indicated) and then 
the patient’s oncologist either received the polypharmacy 
recommendations and was provided time to discuss them 
with the patient (intervention group) or they did not 
receive the recommendations (control). Despite the small 
number of patients (n=40), the assessment identified 
a significant number of polypharmacy-related concerns. 
The majority of polypharmacy concerns centered around 
supportive care (51% vs 27%, respectively) but it is also 
worth noting that there was a notable difference in the 
discussion surrounding treatment for other comorbidities 
outside of cancer in the intervention arm (52% vs 31%). 
The fact that comorbidities were not discussed as often in 
the control arm could imply that providers may be limited 
with time and therefore unable to address polypharmacy 
during a routine visit. Additionally, the findings indicate 
that polypharmacy is more likely to be addressed if the 
medication review can be done ahead of time or by 
another provider, such as a pharmacist, since routine visits 
rarely allow time for such assessment by the oncologist.
Other research similarly indicates the benefits of sche-
duling time for a medication review that occurs separately 
from other medical care. Yeoh et al examined the impact 
of a medication therapy management (MTM) service for 
ambulatory patients who were 65 or older and found that 
the clinical pharmacist performing the medication review 
with a validated screening tool identified a drug-related 
problem in at least 90% of the patients who took one or 
more chronic medications.31 The pharmacist intervened on 
44 of the 361 identified drug-related problems, with most 
interventions rating some degree of significance (ranging 
from minor significance to very significant). These find-
ings indicate that any older adult with cancer who is taking 
at least one medication is a good candidate for a more 
detailed polypharmacy assessment with a screening tool.
Several studies have compared the tools used to assess 
polypharmacy in older adults in the ambulatory 
setting,32,33 but few have investigated which tools are 
best suited for those with cancer. One study by Whitman 
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et al compared the use of 12 screening assessments in 
older adults with cancer and found that while many of 
the screening tools detected PIMs, these medications may 
actually be benefiting the patient and therefore must be 
considered within the overall context.8 The authors con-
cluded that there is a lack of polypharmacy assessment and 
deprescribing protocols available to target the unique 
population that is older adults with cancer. The findings 
also lend support to having a pharmacist perform the 
medication review, select the most appropriate screening 
tools, and interpret their findings.
Findings of other studies have also demonstrated the 
benefit of using pharmacists to perform medication 
reviews. For instance, a study by Nightingale et al found 
that some screening tools are best used in combination (eg, 
Beers and STOPP) to capture a larger prevalence of poly-
pharmacy that can then be intervened upon.6 When 
a pharmacist, trained to be familiar with the context and 
indications for a medication, used a combination of vali-
dated screening tools, more PIMs were identified and 
rectified. This recommendation is supported by the find-
ings of a pilot study by Whitman et al in which 
a pharmacist implemented a comprehensive geriatric 
assessment of up-to-date and accurate medication lists 
(including prescription, non-prescription, and supple-
ments/complementary alternative medications) for older 
adults with cancer in the outpatient setting.5 The assess-
ment utilized three screening tools, applied in the follow-
ing order, as the scope of each one narrows: the Beers 
Criteria, Screening Tool to Alert doctors to Right 
Treatment (START), STOPP, and the MAI. The authors 
concluded that use of all three screening tools uncovered 
three times more drug therapy problems than any single 
tool alone and produced the most efficient strategy to 
identify inappropriate medication use. The authors also 
noted that supplemental screening tools, such as the 
Choosing Wisely Initiative and the Canadian 
Deprescribing Network, can further assist providers with 
addressing polypharmacy in older adults with cancer.
Literature supports integrating a pharmacist into ambu-
latory healthcare teams. A study by Valgus et al evaluated 
patients’ palliative symptom scores over time following 
integration of a clinical pharmacist on an oncological 
multidisciplinary team in the outpatient setting.34 The 
study had a limited number of patients (n=89), with only 
19 older than 60 years old. The pharmacists in the study 
obtained cognitive assessments, gathered medication his-
tories, and assigned palliative assessment scores. Patient 
symptom evaluation was limited to palliative symptoms, 
not all comorbid conditions. Still, when the researchers 
compared the symptom scores to those from the inpatient 
setting, the scores in the outpatient setting improved after 
a pharmacist was included on the team, highlighting the 
value of a pharmacist-embedded in the multidisciplinary 
approach to treating patients.
In similar study by Mancini, a pharmacist in 
a multidisciplinary oncology clinic assessed the medica-
tions for adult outpatients with cancer and identified dupli-
cate therapies (46.7% of patients), drug interactions (44%), 
side effects (74.7%), lack of efficacy (94.7%), and 
untreated conditions (73.3%).35 The authors concluded 
that a pharmacist can bring value to an outpatient team 
and help other practitioners with their assessments. Again, 
their findings support pharmacists in the medication 
review role, but because the population under investigation 
was not older adult-specific, this study did not provide 
direct evidence of their value for assessing polypharmacy 
in older adults with cancer in the ambulatory setting.
A recent study by Choukroun et al highlights the 
importance of collaboration among different providers 
for reducing polypharmacy and inappropriate medication 
use.36 The prospective study evaluated the impact of hav-
ing a pharmacist and a geriatrician each perform a separate 
medication review as part of a geriatric assessment in 
older adults (median age: 83 years) with solid tumor 
malignancies and an average of four comorbidities. The 
notable difference between the pharmacist and geriatrician 
was that the pharmacist used two validated screening tools 
as part of the assessment. The pharmacists identified 165 
drug therapy problems, most of which were moderately 
(49%) or most severe (0.8%). The authors concluded that 
adding a pharmacist to a geriatrician’s team resulted in 
identification of more drug-related problems versus the 
experienced clinician conducting the medication review 
alone.
Another study by Watkins et al examined the feasibility 
of having pharmacists document MTM activities and sub-
sequently bill for the service.37 The pharmacists, who were 
already integrated within the ambulatory clinics at the 
comprehensive cancer center, performed 239 MTM visits 
over 3 months with patients (average age = 56 ± 13 years) 
who had an oncological diagnosis and at least two other 
comorbidities. Many of the visits were initiated due to 
cancer-related concerns, but this opened the door to assess-
ment of the patient’s other comorbidities so that the patient 
received a comprehensive evaluation from a medication 
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perspective. Implementing the formal MTM documenta-
tion and billing process increased the perceived value and 
visibility of the pharmacist services to the cancer center. 
These findings also highlight the importance of addressing 
not only the primary cancer but also the other comorbid-
ities that patients may be experiencing. Although not spe-
cifically reported in this article or other available literature, 
it can be speculated that medication evaluation beyond 
cancer treatment could translate into a reduced risk of 
hospital admission secondary to poor management of 
other disease states. More literature specifically on older 
patients with cancer is needed.
In the ambulatory setting, there are many opportunities 
for patients to interact with a variety of healthcare profes-
sions. Plenty of data support integration of a pharmacist 
into the geriatric assessment of older adults with cancer, 
similar to inpatient oncology polypharmacy assessment, 
but it is unclear how pharmacists can best support and be 
supported by other members of the team for a true multi-
disciplinary approach that optimizes the care of older 
adults with cancer. Furthermore, a literature gap exists on 
how to best utilize non-pharmacists members of the ambu-
latory healthcare team in geriatric assessment. There 
would also be potential benefit in evaluating older adults 
with cancer from not only an oncological perspective but 
also from a cancer plus comorbidity perspective to 
enhance quality of life and decrease potential adverse 
effects.
Surgical Oncology Setting
The importance of assessing polypharmacy in older adults 
with cancer also applies to surgical oncology as emerging 
evidence suggests that polypharmacy and PIM use are 
significantly associated with postoperative outcomes (eg, 
postoperative complications, delirium, extended length of 
hospitalization, and emergency department visits). Thus, 
a unique opportunity exists for members of the interpro-
fessional surgical oncology healthcare team to optimize 
medication use in order to positively impact patient care. 
A retrospective cohort study by Jeong et al evaluated 
associations between preoperative medication use and 
postoperative length of hospital stay in older adults under-
going cancer surgery.38 An interprofessional care team, 
consisting of geriatricians, nurse specialists, dietitians, 
and pharmacists, conducted a comprehensive preoperative 
geriatric assessment. The pharmacists were responsible for 
performing the medication assessment and evaluating all 
prescription and non-prescription medications, including 
using the 2015 Beers criteria to analyze the number of 
medications, delirium-inducing medications, fall-inducing 
medications, and PIMs. The study reported that cancer 
type and the number of medications, PIMs, and delirium- 
inducing medications were statistically significant factors 
for postoperative length of stay. A similar retrospective 
study by Choi et al examined the relationship between 
preoperative medication use and postoperative institutio-
nalization and death in older adults with cancer.39 The 
study showed that polypharmacy, infection, and transfu-
sions—identified on a preoperative comprehensive geria-
tric assessment conducted by an interprofessional care 
team, including pharmacists conducting the medication 
evaluation—were significantly associated with post- 
discharge institutionalization after adjusting for confoun-
ders. A study by Westley et al investigated rates and 
associated predictors of emergency department visits in 
older women 45-days post breast cancer surgery.40 Some 
of the significant factors associated with emergency 
department visits were cancer stage, mastectomy, poly-
pharmacy, benzodiazepine and anticoagulant use, and 
past hospitalization. The authors concluded that some of 
these factors could potentially be mitigated and amenable 
to early intervention. Another study by Jeon et al exam-
ined the association between preoperative medication use 
and hospital readmission.41 The authors reported that pre-
operative discontinuation-requiring medications (defined 
as medications that should be discontinued before surgery 
due to surgical risks, such as antithrombotic agents for 
postoperative hemorrhage, metformin for lactic acidosis, 
and herbal medications for the uncertainty about their 
actual contents) were associated with unplanned 30-day 
hospital readmission after surgery, despite discontinuing 
medications.
The International Society of Geriatric Oncology devel-
oped a Surgical Taskforce that conducted a survey to 
explore surgical oncologists’ approach towards surgery in 
older adults with cancer, given the ongoing uncertainty 
around cancer management, including under-treatment 
and overtreatment.42 The survey reported a low overall 
response rate (11%, n=251) and revealed that only 6.4% 
of the surgeons who responded used a comprehensive 
geriatric assessment in daily practice. Additionally, colla-
boration with geriatricians was uncommon, despite the fact 
that patient quality of life and functional recovery were 
identified as some of the most important and relevant 
endpoints in this population.
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Combined, this information presents an opportunity for 
oncology surgery service lines to reimagine how interpro-
fessional team members and resources can be utilized to 
improve patient outcomes. Little research has focused on 
medication interventions to reduce polypharmacy and opti-
mize medication management in older adults with cancer 
in the surgical oncology (preoperative) setting.5,6,43–46 But 
it is clear that medication management is a critical com-
ponent of the preoperative screening assessment and the 
postoperative monitoring process. At a minimum, preo-
perative medication assessments should consist of an eva-
luation for polypharmacy and inappropriate polypharmacy. 
Inappropriate polypharmacy can be screened utilizing 
tools such as Beers criteria47 or the STOPP criteria.48 
Both delirium- and fall-inducing medications should be 
identified, with indications for use, so potential deprescrib-
ing could be initiated. In such cases, deprescribing could 
consist of dose tapering, switching to as-needed use, or 
abrupt discontinuation with pre-determined monitoring 
parameters for close follow-up. Additional medications 
that should be assessed and discontinued as part of the 
preoperative process include antithrombotic agents due to 
risk for hemorrhage, metformin due to risk for lactic 
acidosis, exogenous hormones due to risk for thrombosis, 
and herbal medications due to uncertainty around actual 
contents and risk for drug–herb interactions.38
Delivering comprehensive medication management 
services within a surgical oncology practice environment 
does require significant resources, including staff/person-
nel, time, finances and leadership to oversee this high- 
quality service. Although these resources may add costs 
and time to care initially, they may also provide valuable 
benefits postoperatively in the form of improved patient 
outcomes and reduced readmissions rates.
Infusion Center Setting
In infusion centers, pharmacists are involved in the pre-
paration and dispensing of chemotherapy regimens, and 
they also have the opportunity to play a role in identifying 
PIMs in older adults with cancer. It is important for these 
pharmacists to be aware of not only a patient’s chronolo-
gical age but also a patient’s functional age when assessing 
appropriateness of the patients’ regimens. In 2018, the 
Hematology/Oncology Pharmacy Association published 
guidelines that further defined the scope of hematology/ 
oncology practice for pharmacists, including the role of 
infusion center pharmacists.49 The document outlines 
important tasks of the infusion center pharmacist, 
including upholding, maintaining regulation requirements, 
and reviewing a patient’s cancer treatment plan through 
verification and dispensing processes. The document does 
not, however, address concerns related to older patients 
with cancer.
Limited research has explored the role of infusion 
center pharmacists in medication use and assessment. In 
a prospective, descriptive, cross-sectional study by Knez 
et al, pharmacists in a chemotherapy preparation unit were 
shadowed to evaluate the clinical interventions they made 
related to the dispensing of chemotherapy doses.50 The 
problems that the pharmacist identified as requiring an 
intervention mostly related to “drug and therapy” (38%), 
“clerical” (33%), or “dose, frequency, and duration” 
(19%). The oncologist accepted most pharmacist recom-
mendations, implementing them in 86% of the cases. 
These findings highlight the important role of pharmacists 
in reviewing the treatment plan and dispensing of the 
chemotherapy in order to provide quality care to patients 
with cancer. The study did not discuss the importance of 
a full medication review that included reviewing 
a patient’s non-cancer medication regimen, particularly in 
the older cancer patient population (patients in this study 
ranged in age from 24 to 75 years).
A retrospective cohort study by Sokol et al aimed to 
identify the potential for adverse drug reactions and to 
define physicians’ responses to potential DDIs in patients 
at least 70 years of age with multiple comorbidities and 
also receiving chemotherapy. On average, patients had 
three comorbid conditions, most commonly cardiovascu-
lar, pulmonary, and gastrointestinal conditions. The results 
showed that polypharmacy was prevalent in these patients, 
as they took an average of nine medications (prescription 
and non-prescription), most commonly medications for 
treating cardiovascular and gastrointestinal co- 
morbidities. Despite the potential for DDIs, physicians 
made no adjustments to prescriptions.51
Additional studies are needed to further define the role 
of the pharmacist in the infusion center setting, particu-
larly related to polypharmacy and the care of older adults 
with cancer. Likewise, studies could also be conducted to 
define the role of other healthcare providers and how to 
best collaborate in the infusion center setting.
Community Hospital Setting
Community cancer centers differ from larger AMCs and 
designated cancer cancers in regard to resources and staff. 
In particular, community cancer centers often lack 
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a clinical pharmacist who can provide medication assess-
ment specific to the issues facing patients with cancer. The 
literature describing older adult cancer care provided at 
community hospitals is scarce, especially studies reporting 
on medication use and polypharmacy. A retrospective 
study by Loui et al demonstrated that complex oncologic 
resections (defined as esophagogastric, hepatobiliary, pan-
creatic, rectal, and retroperitoneal resections) could be 
safely performed at community hospitals.52 Of the patients 
evaluated, 88 (64.7%) were male and average age was 
65.6 years. The mortality rate was 0.7% (grade 
V complication), the median length of stay for all opera-
tions was 8 days, and the hospital readmission rate within 
30 days of initial discharge was 2.9%. The authors did not 
discuss medication assessments nor did they discuss inap-
propriate polypharmacy, delirium or falls as part of the 
study outcomes. A similar study by Hardacre et al evalu-
ated 60-day outcomes associated with a pancreatic surgery 
program at a 144-bed community, non-teaching hospital 
compared to a tertiary medical center.53 The authors 
reported that there were no mortalities at either hospital, 
and major complications, reoperation rates, and readmis-
sion rates did not differ between the two hospitals.53 They 
did not report preoperative medication assessments nor 
delirium or falls as part of the study outcomes.
A study by Chung et al reported on a practice model 
change within a community hospital aimed to meet quality 
and safety goals.54 The practice change involved an inter-
professional team of nurses, pharmacists, and physicians 
that developed standardized order sets, protocols, opera-
tions, and chemotherapy, along with collaborative practice 
agreements. This practice model change resulted in a 45% 
reduction in chemotherapy errors and found that the most 
common cause of errors was missing information (eg, 
omission of drug duration or frequency, dose, route, or 
premedication). The pharmacists reported that, prior to the 
practice model change, they did not feel empowered to 
make clinical recommendations on dose modification or 
provide specific oncology drug information, and after the 
changes were implemented, they had the tools to perform 
clinical monitoring and communicate recommendations to 
oncology physicians and providers.54 This study did not 
include information on structured medication assessments 
for non-chemotherapy drugs and did not report how the 
practice model change influenced patient outcomes.
We also uncovered literature on the development of 
a senior adult oncology program within a community can-
cer center. A pilot study by Lynch et al described the 
development of a specialized program for older adults 
within a community cancer center.55 The program was 
designed to identify and treat cancer and comorbidities, 
geriatric syndromes such as malnutrition and polyphar-
macy, and educate patients, families, and the community, 
among other goals.55 It consisted of a unique model of 
service including a nursing assessment, social work eva-
luation, psychological evaluation, nutrition counseling, 
and prescription guidance, however the program did not 
mention whether a pharmacist was a member of the inter-
professional care team. The patients who participated in 
the pilot experienced a variety of medical issues, with the 
most common related to nutrition (n=19) and medication 
assistance (n=130).55 Details regarding polypharmacy 
were not included, and medication-related interventions 
were not reported.
Recognizing that community cancer centers may not 
have the same amount of resources or number of cancer 
care providers, specialists, and allied healthcare profes-
sionals (eg, clinical pharmacists, dieticians, social workers, 
care navigators), few studies have evaluated the benefit of 
clinical pharmacy services at a community oncology 
clinic. A retrospective descriptive study by Ruder et al 
analyzed the impact and cost savings of having a clinical 
pharmacist on staff to consult regarding clinical interven-
tions and consultations at a community oncology clinic.56 
Interventions included medication reconciliation, dosing, 
and side effect prevention and management, and consulta-
tions involved patient visits and patient education. Of the 
583 interventions reported, 131 were related to adverse 
events, 52 were related to medication reconciliation, and 
22 were dose-related. Patient et al surveys revealed posi-
tive ratings for clinical pharmacy services.56 This study 
did not report patient demographic information, such as 
median age, and did not include information on polyphar-
macy and inappropriate polypharmacy. The study did, 
however, demonstrate that the presence of a clinical phar-
macist (versus a pharmacist who is solely responsible for 
admixing and dispensing parenteral chemotherapy) opens 
up opportunities to optimize the quality of cancer care for 
patients and to improve drug information and education to 
fellow healthcare providers.
Palliative Care and Hospice Setting
Many clinicians are daunted by the prospect of managing 
polypharmacy and PIMs in persons who are nearing or are 
at the end of life.57 Cancer care and medication manage-
ment in this population is complex due to a number of 
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different factors. These include a rise in the number of 
comorbidities at the end of life, an increase in the potential 
for medication adverse effects and geriatric syndromes, 
conflicting goals of care between providers and patients, 
and poor approximation of life expectancy. The incidence 
of PIM use in older adults with cancer, specifically in the 
palliative care and hospice settings, has been found to 
range from 22% to 95%.58 However, the criteria for PIM 
identification, as well as the process for deprescribing, are 
inconsistent between studies. Outcomes data are also 
sparse in this population.59–61
Despite these limitations, several deprescribing frame-
works have been developed that provide an opportunity for 
future research in older adults with cancer. A framework 
developed by Lindsay et al62 aims specifically to assist 
clinicians in recognizing PIMs and guide rational depre-
scribing in palliative oncology patients. Called OncPal, the 
guideline is geared towards patients with a life expectancy 
of less than 6 months; therefore, it is applicable in both the 
palliative and hospice settings. The initial study compared 
the use of the OncPal Deprescribing Guideline to expert 
assessment (palliative care, radiation oncology, and medi-
cal oncology clinicians) and found that the OncPal guide-
line assessed PIMs correctly 94% of the time 
comparatively. The incidence of PIMs in this study was 
70%, with the most frequently flagged drug classes for 
deprescribing intervention being antihypertensives, dysli-
pidemic agents, and complementary and alternative thera-
pies. The medication class found to be the most discordant 
between the OncPal guideline and the expert panel was 
neoplastic/immunomodulator oral anticancer treatments. 
Preliminary data suggest an important role of the OncPal 
deprescribing guideline, yet additional studies are needed 
to validate its use in different care settings.
The Good Palliative-Geriatric Practice (GP-GP) algo-
rithm is a well-validated tool potentially applicable to 
older adults with cancer in the palliative care setting. 
The tool consists of a number of targeted statements 
questioning medication appropriateness. An initial study 
by Garfinkel63 using the GP-GP algorithm focused on 
reducing polypharmacy in older adults in geriatric inpa-
tient units. The algorithm was applied in 119 patients 
(intervention group) versus 71 patients in a control, non- 
intervention group. A total of 332 medications were 
deprescribed in the 119 patients, averaging 2.8 medica-
tions per patient, and the rate of deprescribing failure was 
10%. The 1-year mortality rate was 21% in the interven-
tion group versus 45% in the control group, and the rate 
of referral to a higher level of care was 11.8% in the 
intervention group versus 30% in the control group.63 
A subsequent study by Garfinkel64 validated the use of 
the GP-GP algorithm in community-dwelling older 
adults. This study excluded patients with advanced dis-
ease (including cancer), thus reducing generalizability to 
the geriatric oncology population. Finally, a study by 
Bilek et al65 found that providing physicians a one-day 
workshop on the use of the GP-GP algorithm successfully 
promoted deprescribing efforts in both the inpatient and 
outpatient setting. Trained physicians had a high inci-
dence of deprescribing benzodiazepines, psychotropics, 
and antihypertensives. About a quarter of patients in this 
study were older adults with cancer.
A deprescribing framework by Holmes et al66 has been 
applied to older adults with cancer. This model uses four 
“pillars” of medication appropriateness to determine correct 
prescribing and deprescribing: remaining life expectancy of 
the patient, time until benefit of the medication, individual 
patient goals of care, and the intended target of the treatment 
(eg, palliative in nature vs preventative care). The framework 
by Holmes et al66 has been utilized in at least one study in 
older adults with cancer.5 This study was multidisciplinary in 
nature and included input on the four components of medica-
tion appropriateness by a geriatric oncologist, pharmacist, 
nurse, physical therapist, and patients/caregivers.
In addition to applicable frameworks in the palliative 
oncology population, specific studies have assessed the 
impact of reducing pill burden and eliminating unneces-
sary medications in the hospice setting and in patients 
imminently dying of cancer.67,68 A study from 2009 by 
Riechelman et al found that one in five ambulatory 
patients with cancer with an estimated life expectancy of 
2 months or less were taking a “futile” medication.59 The 
authors defined medically futile as “an intervention that no 
longer provides patient benefit, does not achieve 
a valuable goal, has a potential for harm and lacks benefits 
to justify resources” and retrospectively reviewed the med-
ication lists of 372 older patients with cancer who were 
seen in a palliative care clinic and evaluated whether the 
medications they were taking were indeed futile. They 
found that 22% (n=82) of the patients were taking at 
least one futile medication at the end of life.
A retrospective review by DeAngelis et al assessed con-
tributing factors potentially leading to hospital readmission in 
75 patients admitted to hospice. The authors identified three 
main reasons for readmission: medication-related problems, 
unanticipated new medical problems, and uncontrolled 
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symptoms. Interestingly, 33 of the patients (45%) presented 
with uncontrolled symptoms, thereby requiring reinitiating 
therapy previously deprescribed upon hospice admission.69 
The conclusions of this study are supported by two 
others,70,71 but despite this, few studies have reported out-
comes of inappropriate deprescribing in the hospice 
population.
There is a gap in the literature describing which 
member(s) of the healthcare team are best equipped to 
manage polypharmacy and PIMs in this population. In 
one study that touches upon the concepts of older adults 
with cancer, polypharmacy, and chronic disease state man-
agement at the end of life, the authors point out that the 
general practitioner is often unwilling to alter cancer- 
related treatment, and in turn the oncologist is often 
unwilling to alter any non-cancer-related treatment, 
thereby putting the patient at risk of continued polyphar-
macy with potential adverse outcomes.72 The findings of 
the study highlight that polypharmacy is often not 
addressed until the end of life and beg the question 
“whose responsibility is it to address polypharmacy?” 
The authors conclude that a patient’s primary care physi-
cian should be assessing polypharmacy prior to the end-of- 
life phase of care.
Huisman et al recently explored the role of the hospice 
nurse in medication management and deprescribing 
interventions.73 The authors performed a qualitative interview 
study to summarize perspectives of patients, caregivers, and 
healthcare providers on the nurse’s role in medication manage-
ment in the hospice setting. The study was a secondary ana-
lysis for the “MEDIcation management in the LAST phase of 
life (MEDILAST)” study. The authors performed 76 inter-
views with patients (n=17), nurses (n=20), medical trainees 
(n=20), informal caregivers (n=12), and family physicians 
(n=12), and the recorded interviews were analyzed and 
coded based on relevancy. The notable emerging themes iden-
tified via the interviews included the nurse’s role in identifying 
medication burden at the end of life; educating the patient on 
medication adjustments and the monitoring that will follow; 
monitoring for medication side effects; and the direct impact 
on quality of life. The interviews revealed that the hospice 
nurse plays a role in delegating medication management to the 
caregiver in some cases and in keeping them educated on 
when to administer “emergent” medications. Additionally, 
the hospice nurse can propose changes in medication therapy, 
such as the route of administration when the patient is no 
longer able to swallow, and empower the patient and care-
givers on as-needed medication administration. Ultimately, the 
authors concluded that the nurse plays a large role in the 
patient’s end-of-life medication management and quality of 
life.
In summary, based on available information, medication 
management roles for pharmacists, providers, and nurses 
appear balanced in the palliative oncology and hospice set-
tings. For future studies, existing frameworks in palliative 
oncology should be utilized and compared across different 
cancer care settings, particularly emphasizing outcomes of 
deprescribing and deprescribing failure.
Specialty Pharmacy Setting
Specialty pharmacies have grown immensely over the past 
four decades, establishing their role in healthcare delivery. 
These pharmacies are able to work with providers and 
insurers alike to ensure patient access to therapy and to 
address issues regarding financing and delivery of the 
medication, including oncology medications.74 However, 
as these pharmacies have become more popular, patients 
may fill their medications at multiple pharmacies. 
Inadequate communication among pharmacies and provi-
ders may lead to therapeutic duplication or prescribing of 
medications with significant DDIs.75 This lack of commu-
nication among health care professionals may be particu-
larly problematic for older adults with cancer who often 
have multiple chronic conditions and take many 
medications.76
There are limited data regarding polypharmacy in older 
adults with cancer utilizing specialty pharmacies. 
However, according to the National Comprehensive 
Cancer Network Specialty Pharmacy Task Force, the pri-
mary goals of specialty pharmacies are to ensure the 
appropriate use of medications, maximize drug adherence, 
enhance patient satisfaction through direct interaction with 
healthcare professionals, minimize cost impact, and opti-
mize pharmaceutical care outcomes and delivery of 
information.77 These goals can be further defined to 
apply to older patients with cancer. For example, ensuring 
the appropriate use of medications may include the use of 
tools such as the Beer’s criteria, STOPP/START criteria 
and the MAI.77 Nonadherence to medication therapy can 
occur in all patient populations, but is particularly com-
mon in the older adult population because they have a high 
number of comorbid conditions.78 In patients with cancer, 
adherence to their anticancer and supportive care regimens 
is imperative to the success of their treatment course. 
Therefore, in older adults with cancer utilizing specialty 
pharmacies, the ability to assess and address nonadherence 
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is particularly important. A retrospective analysis of 
a specialty pharmacy program by Tschida et al compared 
patients who used specialty pharmacies to those who used 
retail pharmacies for their oral cancer regimen.79 
Pharmacist involvement included biweekly phone calls 
with the patients to assess adherence, provide education, 
and manage side effects. The study showed that the use of 
specialty pharmacy was associated with improved oral 
oncology medication adherence, as well as a decrease in 
healthcare costs. However, identifying drug–drug interac-
tions, reviewing a patients’ non-cancer medications, and 
assessing polypharmacy was not discussed in the study.
When a cancer patient utilizes a specialty pharmacy, 
that pharmacy takes on an integral role in the care of 
these patients as they may communicate with the patient 
regularly regarding their anticancer or supportive care 
regimen, including discussion of adverse events and 
toxicities. However, the use of specialty pharmacies 
could contribute to siloes or fragmented healthcare. It 
is imperative that specialty pharmacies communicate 
effectively and relay relevant information gleaned from 
their patient interactions to the patient’s entire oncology 
team. This communication creates an opportunity for 
those involved in the care of these oncology patients to 
collaborate with specialty pharmacies to ensure that 
a patient has continued access to their medication and 
that therapy adjustments, including temporarily holding 
therapy, are appropriately communicated. Additionally, 
there may be a unique opportunity for all involved to 
ensure that a patient’s therapy is appropriate not only for 
their chronological age but also their functional age 
including their unique social, psychosocial, and financial 
situations.
Conclusion
Existing data suggest a variety of clinician roles in managing 
polypharmacy and other medication-related problems in 
older adults with cancer. The impact of clinical pharmacists 
in this population is particularly evident in the academic 
inpatient, ambulatory, and palliative care settings. The extent 
of non-pharmacist clinician involvement varies significantly 
based on the care setting. Established themes for providers 
related to polypharmacy and deprescribing interventions 
include the need for enhanced awareness of potential harms 
of high-risk medications and the need for breaking patterns 
of inappropriate prescribing in all care settings. Studies eval-
uating nursing care suggest positive roles for empowering 
patients to bring forth medication concerns to their providers, 
flagging new potential medication side effects, and collabor-
ating closely with pharmacy colleagues. Future studies are 
needed to determine ideal processes for polypharmacy 
assessment and deprescribing in the infusion center, specialty 
pharmacy, and surgical oncology settings, in particular. 
Additionally, structured studies are needed that examine the 
current state of polypharmacy education in healthcare across 
all health professions.
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